Neoadjuvant SHR-A1811 Combined With Pertuzumab in HER2-Positive Breast Cancer: An Exploratory Clinical Study.
Hebei Medical University Fourth Hospital
Hebei Medical University Fourth Hospital
University of Washington
Institut Paoli-Calmettes
Harbin Medical University
Indiana University
Mayo Clinic
Affiliated Hospital of Nantong University
West China Hospital
Sun Yat-sen University
Tianjin Medical University Cancer Institute and Hospital
Fudan University
University of Miami
Second Affiliated Hospital, School of Medicine, Zhejiang University
University Hospital, Grenoble
Institut Curie
M.D. Anderson Cancer Center
Mayo Clinic
Institut Bergonié
Fudan University
Fudan University
Shandong Cancer Hospital and Institute
Arab American University (Palestine)
Harbin Medical University
Tanta University
Helwan University
Université de Sherbrooke
Peking Union Medical College Hospital
Shengjing Hospital
M.D. Anderson Cancer Center
Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation
Sun Yat-sen University
Sun Yat-sen University
Sun Yat-sen University
Fudan University
Fujian Medical University
The Greater Poland Cancer Centre
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
University of Valencia
Affiliated Hospital of Qinghai University
ImmuneOnco Biopharmaceuticals (Shanghai) Inc.
European Institute of Oncology
Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
GBG Forschungs GmbH
University of Wisconsin, Madison
Second Affiliated Hospital of Guangzhou Medical University
Tianjin Medical University Cancer Institute and Hospital
SOLTI Breast Cancer Research Group
Fudan University
Fudan University
Shengjing Hospital